‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data

‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data — Live Feedhttps://www.live-feeds.com/feed/it-is-what-it-is-merck-exec-unruffled-by-unfortunate-leak-of-esmo-cancer-vaccine-dataContinuously updated, source-cited coverage. Merck Unruffled by Cancer Vaccine Data Leak Ahead of ESMOhttps://www.live-feeds.com/feed/it-is-what-it-is-merck-exec-unruffled-by-unfortunate-leak-of-esmo-cancer-vaccine-datahttps://www.live-feeds.com/feed/it-is-what-it-is-merck-exec-unruffled-by-unfortunate-leak-of-esmo-cancer-vaccine-data#u159613Wed, 28 Oct 2026 09:10:44 +0000A high-profile data leak ahead of the European Society for Medical Oncology congress temporarily disrupted markets for Merck and Moderna, but executives and financial analysts remain unruffled. The partners revealed detailed results from the Phase 3 INTerpath-001 trial evaluating their personalized mRNA cancer vaccine for melanoma. Initial stock selloffs reversed as analysts warmed to the trial data following the official presentation in Madrid. The therapy successfully cut the risk of melanoma recurrence or death by 42% in the Phase 3 trial.Why it mattersMerck and Moderna prepared for major h